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Abstract
The use of multiple imputation has increased markedly in recent years, and journal reviewers may expect to see multiple
imputation used to handle missing data. However in randomized trials, where treatment group is always observed and
independent of baseline covariates, other approaches may be preferable. Using data simulation we evaluated multiple
imputation, performed both overall and separately by randomized group, across a range of commonly encountered
scenarios. We considered both missing outcome and missing baseline data, with missing outcome data induced under
missing at random mechanisms. Provided the analysis model was correctly specified, multiple imputation produced
unbiased treatment effect estimates, but alternative unbiased approaches were often more efficient. When the
analysis model overlooked an interaction effect involving randomized group, multiple imputation produced biased
estimates of the average treatment effect when applied to missing outcome data, unless imputation was performed
separately by randomized group. Based on these results, we conclude that multiple imputation should not be seen as the
only acceptable way to handle missing data in randomized trials. In settings where multiple imputation is adopted, we
recommend that imputation is carried out separately by randomized group.
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1 Introduction
Research articles and guidance documents have emphasized the role of prevention in minimizing the impact of
missing data,1–4 but most randomized controlled trials (RCTs) have some missing data.5 Given the potential for
biased and inefficient treatment effect estimates, it is crucial that missing data are handled appropriately during the
analysis.
All statistical analyses involve assumptions about the mechanism responsible for the missing data. Rubin6
introduced three classes of mechanisms for missing data: missing completely at random (MCAR), where the
probability of missingness is unrelated to observed or unobserved data; missing at random (MAR), where the
probability of missingness is unrelated to unobserved data conditional on observed data; and missing not at
random (MNAR), where the probability of missingness depends on unobserved data conditional on observed
data. Since MAR and MNAR cannot be distinguished from observed data, it is essential that the assumptions of
the analytic approach are scientifically plausible and clearly stated.7,8 To assess the robustness of findings to the
assumption made about the missing data mechanism in the primary analysis of an RCT, additional sensitivity
analyses are strongly recommended.7–11
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Multiple imputation (MI)6 is a statistical approach to handling missing data that has been widely adopted
due to its flexibility and ease of implementation.12,13 MI involves fitting a statistical model to the observed data
and using it to estimate values for the missing data. To incorporate missing data uncertainty, multiple values are
imputed for each missing observation, producing multiple complete datasets. Following analysis of these
datasets using standard complete data techniques, the multiple parameter estimates are combined using Rubin’s
rules6 to give a single MI estimate. Standard implementations of MI assume that data are MAR, although it can
also be applied under an MNAR assumption.6 Provided the assumption about the missing data mechanism is met
and models used for imputation and analysis are correctly specified, MI produces consistent and asymptotically
efficient parameter estimates with nominal coverage.6 Of the various methods of imputation available, MI based
on the multivariate normal distribution14 and MI by chained equations15–17 are most commonly used in RCTs.18
With the use of MI in RCTs rising dramatically in recent years,12,18,19 editors and journal reviewers may expect
to see MI used to handle missing data. Indeed, we are aware of several recent instances where reviewers have
pushed with little justification for trial data to be re-analysed using MI. However, whether MI should be viewed as
the gold standard approach for handling missing data in RCTs is questionable. Importantly, results derived in
general regression settings supporting the use of MI may not be applicable to RCTs. Unlike observational studies,
the key exposure in RCTs (randomized group) is always observed and known to be independent of baseline
covariates. In addition, missing data occur primarily in the outcome variable, although baseline covariates may
also have missing data. Under these conditions, some of the value of MI may be lost and other methods of analysis
may be preferable.
Another uncertainty around the use of MI in RCTs is whether imputation is best carried out across all
participants or separately by randomized group. If subgroup analyses are of interest, it is essential that
interaction terms are accounted for in the imputation process to avoid biasing interaction tests towards the
null. Rather than specifying interaction terms within the imputation model, several authors have recommended
fitting separate imputation models within each randomized group.11,20–22 This strategy is appealing due to its
simplicity and ability to facilitate subgroup comparisons for any baseline covariate included in the imputation
model. Unfortunately its performance is not well understood, and it is unclear how imputation should proceed
when subgroup analyses are not of interest and the intention is to only produce average treatment effects (ATEs)
from main effects models.
This article describes the performance of MI in the RCT setting, covering the common scenarios of missing data
in an outcome measured once or repeatedly over time and missing data in a baseline covariate. Using a series of
illustrative data simulations and a case study, we compare MI with other standard approaches for handling
missing data and explore the merits of imputing overall and separately by randomized group. Throughout we
assume that missing data are unplanned rather than by design, and that interest lies in estimating the effect of
treatment according to the intention to treat (ITT) principle. If treatment discontinuations occur, we therefore
assume the aim is to estimate a ‘de facto’ estimand23,24 and that data are equally available before and after
treatment discontinuations; we consider the case where data cannot be collected after treatment discontinuation
in the discussion. For missing outcome data, we restrict attention to settings where they are assumed to be MAR,
since this assumption is often made in the primary analysis of an RCT and corresponds with the standard
implementation of MI.
The remainder of the article is structured as follows. Section 2 describes issues in adhering to the ITT principle
in the presence of missing data and implications for the use of MI in RCTs. Section 3 defines key notation and
outlines general simulation methods for evaluating the performance of MI. Section 4 focuses on the performance
of MI for handling missing data in an outcome measured at a single time point. Section 5 considers missing data in
an outcome measured repeatedly over time and the use of auxiliary variables in MI, while Section 6 focuses on
missing data in a baseline covariate for adjustment. Section 7 shows the application of MI to the DINO trial.
Finally, conclusions and general recommendations are provided in Section 8.
2 Intention to treat and missing data
The goal of ITT, or analyzing as randomized, is to maintain the balance in prognostic factors achieved by
randomization, which is critical for avoiding selection bias and establishing causation.25,26 In addition to
preserving the benefits of randomization, an ITT analysis may better inform changes in subsequent clinical
practice, where patients do not always comply with treatment. Following the ITT principle entails estimating
the ITT estimand, which is defined as the average effect of randomization, irrespective of treatment received,
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over all randomized individuals.27 Due to fluctuating use of the term ITT, this has more recently been described as
a de facto estimand.23,24 Interest in the ITT estimand has implications both for trial conduct and analysis. First,
attempts should be made to collect outcome data on all randomized participants, irrespective of adherence to the
protocol.7,8,27 For example, outcome data should still be retrieved for participants that discontinue or switch
treatments during the course of a trial. Second, all collected outcome data should be included in the analysis,
including data from participants that deviate from the protocol.7,8,27 Although there are settings where it may not
be feasible to measure outcomes following a protocol deviation, or where exclusion of collected outcome data may
be justifiable, we do not tackle these scenarios in this article.
Despite efforts to collect data on all randomized participants, invariably there will be some missing data.
Exactly what constitutes an ITT analysis in the presence of missing data has been much debated.28 Some
researchers have suggested that missing outcome data ought to be imputed, so that the full randomized sample
can be included in the analysis.26,29,30 Others have argued that imputation is unnecessary and that an ITT analysis
need only provide a valid estimate of the ITT estimand.7,8,31 Given recent commentary on the importance of
defining and validly estimating the causal estimand of interest,8 and noting that none of the current guidance
documents strictly recommend imputing missing outcomes, we adopt the second view. In differentiating between
competing statistical methods, we therefore focus on their capacity to provide an unbiased and precise estimate of
the ITT estimand rather than their ability to include all randomized participants.
3 Methods
3.1 Setting
Let Yi and Xi define values for the ith participant (i¼ 1 to n) on an outcome variable and a baseline variable,
respectively. Assume the ith participant is randomized independently to treatment group Ti (0¼ control, 1¼ new
treatment) with probability 0.5. Let MYi and MXi denote whether Yi and Xi are missing or observed (1¼missing,
0¼ observed). In the absence of missing data, suppose the adjusted analysis model
gðiÞ ¼ 0 þ 1Ti þ 2Xi ð1Þ
is of interest, where i ¼ EðYijTi,XiÞ and g is an appropriate link function. Of principal importance is the
(adjusted) treatment coefficient 1. Note we focus primarily on adjusted estimates in this article, since
adjustment for pre-specified baseline covariates is common and can lead to substantial increases in power for
testing the effect of treatment.32,33 As conclusions about treatment are typically based on main effects models,1 we
also restrict attention to analysis models that do not include interaction terms.
3.2 MI
In the first stage of MI, multiple values (m> 1) for each missing observation are independently simulated from an
imputation model. For missing data restricted to the outcome, the imputation model would typically regress
observed values of Y on X and T. Additional auxiliary variables that are not in the analysis model can also be
added to the imputation model to improve the prediction of missing values. Let ĉ denote the parameter estimates
from the imputation model and cj (j¼ 1 to m) random draws from the posterior distribution of c. For each
random draw, missing values in Y are replaced by simulated values from the posterior predictive distribution of Y
according to cj . For missing data restricted to a baseline covariate, the imputation model instead describes the
conditional distribution of X according to Y and T. If MI is performed separately by randomized group, T is
omitted from the separate imputation models.
In the second stage of MI, the intended analysis is performed on each of the m complete datasets, in this
case model (1). Let ̂j denote the estimate of 1 from the jth imputed dataset and Wj the corresponding variance
estimate. Using Rubin’s rules,6 the combined MI treatment effect estimate ̂ is calculated as the mean of the m
estimates, i.e. ̂ ¼ 1=m
Pm
j¼1 ̂j: The variance is given by var ̂
 
¼Wþ B 1þ 1=mð Þ, whereW ¼ 1=m
Pm
j¼1 Wj is the
average within-imputation variance and B ¼ ðm 1Þ1
Pm
j¼1ð̂j  ̂Þ
2 the between imputation variance. Hypothesis
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3.3 General simulation methods
Simulation studies were undertaken to describe the performance of MI for handling missing data in a univariate
outcome (Section 4), a multivariate outcome (Section 5) and a baseline covariate (Section 6). For each scenario,
2000 datasets of size n¼ 600 were generated, with 300 observations allocated to each group. The sample size was
chosen to be similar to that of a case study (see Section 7) and to represent a medium-sized trial. Three statistical
methods were considered across all settings based on the adjusted analysis model (1): complete case analysis
(CCA), MI performed overall and MI performed by randomized group. For MI, linear and logistic regression
were used for the imputation of continuous and binary variables, respectively, with m¼ 50 imputations based on
the rule of thumb that the number of imputations should at least equal the percentage of missing data.17
Completed datasets were analysed using linear and logistic regression as appropriate, with treatment effect
estimates combined using Rubin’s rules.6 Performance was evaluated in terms of bias, empirical standard error
(SE), power and the coverage of estimated 95% confidence intervals. Based on 2000 simulated datasets, on 95% of
occasions the coverage is expected to lie between 0.94 and 0.96 for a true coverage of 0.95. All analyses were
performed in SAS version 9.3 (SAS Institute, Inc., Cary, North Carolina).
4 Missing data in a univariate outcome
When a univariate (once-measured) outcome is MAR conditional on fully observed covariates, a correctly specified
CCA with covariate adjustment produces unbiased and efficient estimates of regression parameters.34–36 It has also
been shown that MI with a large number of imputations approximates a CCA in this setting, provided that
imputation and analysis models are the same.37 Using data simulation, we verify these results for RCTs, explore
the implications of imputing overall or by randomized group and investigate settings where the analysis model is
misspecified.
4.1 Correctly specified analysis model
Data were simulated from the model Yi ¼ 0:30Ti þ 2Xi þ ei, with X and e  Nð0, 1Þ. To assess whether model
performance depended on the strength of association between X and Y, 2 was varied so that
corr X,YjTð Þ ¼ 0:30 or 0:70. Since comparisons were insensitive to the treatment effect, 1 was fixed at 0.30 to
reflect a small effect size. Following generation of complete datasets, values in Y were set to missing according to
three MAR mechanisms:
(1) MAR X: Odds of missing Y increase by a factor l per standard deviation (SD) increase in X.
(2) MAR XþT: Odds of missing Y are l times higher in the control group and increase by a factor l per SD
increase in X.
(3) MAR XT: Odds of missing Y are l times higher for treatment group participants with X  0 and for control
group participants with X4 0.
Each missingness mechanism was simulated using a logistic regression model, with l¼ 1.5 or 2.5 to indicate weak
and strong mechanisms, respectively, and with the model intercept varied to produce 20% (realistic) or 50% (extreme)
missing data. This resulted in 24 simulation scenarios (12 missing data scenarios and two values for 2). Supposing
that X is a measure of disease severity, the MAR X and MAR XþT mechanisms might reflect settings where
participants with more severe disease or randomized to the control group are more likely to have missing outcome
data. The MAR XT mechanism could apply in settings where treatment group participants with less severe disease
are also more likely to have missing outcome data due to a perceived lack of need to continue treatment.
As expected, CCA, MI overall and MI by group all produced unbiased treatment effect estimates across the 24
simulation scenarios, with coverage probabilities remaining close to 0.95 throughout (range 0.94, 0.96). Compared
to CCA, empirical SEs were on average 0.4% and 2.7% larger with MI overall and MI by group, respectively,
which translated to an average loss of power of 0.8% for MI overall and 2.6% for MI by group. Figure 1 shows
the performance of the various approaches in scenarios with 50% missing data, a strong MAR mechanism and
where corrðX,YjTÞ ¼ 0:70; these more extreme scenarios were chosen to highlight differences between approaches.
Results from an unadjusted CCA are also displayed for comparison. In all figures, note that error bars indicate
estimation efficiency (1 empirical SE). Unsurprisingly, MI offered no advantages over a CCA across the range of
missingness mechanisms. Of note, unadjusted CCA produced biased estimates when the probability of missing
data depended on X and T, with coverage dropping to 0.39 under the MAR XT mechanism.
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Similar results were obtained from a simulation study involving a binary outcome (online Appendix A).
4.2 Misspecified analysis model, continuous outcome
We now consider settings where an interaction between X and T is overlooked in favour of producing an estimate
of the ATE. This approach is common in practice, since ATEs are commonly used to draw conclusions about
treatment and are of greater relevance to policy-related questions.1,38 Further, tests of interaction are often viewed
as exploratory and can be underpowered.1 For effect modification by discrete X, we assume that interest lies in
estimating the ATE given by
P
X XX, where X ¼ PðX ¼ xÞ and x denotes the ITT estimand for X ¼ x.
Considering binary X with 0 ¼ 1 ¼ 0:5, data were generated from the model Yi ¼ 1Ti þ 0:30Xiþ
3XiTi þ ei, where e  Nð0, 1Þ. Fixing the ATE at 0.30, we investigated both weak (1 ¼ 3 ¼ 0:20 or
equivalently 0 ¼ 0:20, 1 ¼ 0:40) and strong (1 ¼ 0,3 ¼ 0:60 or 0 ¼ 0, 1 ¼ 0:60) interaction effects between
X and T. Following generation of complete datasets, values in Y were set to missing according to the mechanisms
described in Section 4.1. Analysis model (1), misspecified due to the absence of the interaction term between X and
T, was the substantive model of interest.
Across all simulation scenarios MI by group produced unbiased estimates of the ATE with nominal coverage
(coverage range 0.94, 0.96). In contrast, CCA and MI overall produced biased estimates under the MAR X and
MAR XþT mechanisms. Figure 2 illustrates performance for the MAR X mechanism in scenarios with 50%
missing data. As seen in the figure, the bias of CCA and MI overall increased with the strength of the missing data
mechanism and the degree of effect modification. For a strong missing data mechanism and a strong interaction,
the ATE was estimated to be 0.17 (absolute bias¼ 0.13), with coverage dropping to 0.81 for both approaches.
Similar results were observed with 20% missing data, although predictably biases were smaller in magnitude
(absolute bias 0.06). Instead of estimating the desired ATE, CCA and MI overall produced an estimate that
was weighted by the probability of missing data within strata defined by X and T. In particular, the estimated ATE
was proportional to
P
X XXR0XR1X=ðR0X þ R1XÞ, where RTX ¼ PðMY ¼ 0jT ¼ t,X ¼ xÞ. No bias was observed
for these approaches for the MAR XT mechanism, since R00 ¼ R11 and R10 ¼ R01 under this mechanism.
Figure 1. Mean treatment effect estimates for 50% missing data in a continuous outcome, corr(X,YjT)¼ 0.70, strong missing at
random (MAR) mechanisms, correctly specified analysis model. Error bars correspond to empirical standard errors (1 standard
error) across 2000 simulated datasets.
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Although the bias of MI overall could be eliminated by including the interaction term in the imputation model
(results not shown), this may not be an obvious strategy if subgroup analyses are not of interest.
4.3 Misspecified analysis model, binary outcome
For binary outcomes, the notion of an ATE from a misspecified logistic regression model is more complex.
Assuming effect modification by discrete X, omission of the interaction effect from the analysis model can lead
to an ATE estimate that differs substantially from a weighted average of stratum specific effects (on both odds and
log odds scales). In this setting, we consider the ATE that would have been observed with complete data as the
‘least false’ ATE. In the presence of missing data, we assume the goal is to reproduce this least false ATE.
Considering binary X with 0 ¼ 1 ¼ 0:5, data were generated from the model logit PðYi ¼ 1Þ ¼
1:77þ 1Ti þ 0:69Xi þ 3XiTi. The intercept value was chosen so that P Y ¼ 1jT ¼ 0ð Þ ¼ 0:20, while the
coefficient for X gives ORðY,XjT ¼ 0Þ ¼ 2:0. Fixing the average of the stratum specific effects on the logit
scale at 0.69 (OR¼ 2.0), we evaluated both weak (1 ¼ 3 ¼ 0:46) and strong (1 ¼ 0, 3 ¼ 1:38) interaction
effects between X and T. Following generation of complete datasets, values in Y were set to missing according
to the mechanisms described in Section 4.1.
Across the 24 simulation scenarios (12 missing data scenarios 2 interactions), MI by group was unbiased in
reproducing the least false ATE (absolute bias 0.02), with coverage remaining close to 0.95 (range 0.94, 0.96).
In contrast, CCA and MI overall produced biased estimates under the MAR X and MAR XþT mechanisms.
Figure 3 summarizes performance under the MAR X mechanism for 50% missing data. In parallel with results for
continuous outcome data, the bias of CCA and MI overall increased with the strength of the missing data
mechanism and the interaction between X and T.
5 Missing data in a multivariate outcome and use of auxiliary variables
We now consider missing data in an outcome measured at repeated intervals following randomization, where
interest concerns the effect of treatment at the final time point. Unlike the univariate case, the validity of CCA is
Figure 2. Mean average treatment effect estimates for 50% missing data in a continuous outcome under the MAR X mechanism
(odds of Y missing 1.5 (weak MAR) or 2.5 (strong MAR) times higher per standard deviation increase in X), incorrectly specified
analysis model. Error bars correspond to empirical standard errors (1 standard error) across 2000 simulated datasets.
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questionable in this setting since it cannot incorporate information from intermediate measures of the outcome.
Such measures may be associated with the probability of missing data and the value of the outcome at the final
time point. By exploiting information in partially observed cases, MI and likelihood-based approaches have been
favoured over CCA for the analysis of multivariate outcomes.9,11,39,40 In what follows, we briefly introduce
likelihood approaches for multivariate outcome data, describe the link between intermediate outcome measures
and auxiliary variables, and present results from a simulation study comparing MI with alternatives.
Likelihood-based estimation of a linear mixed model (LMM)41 is a popular alternative to MI for handling
missing data in a multivariate outcome. Based on the multivariate normal distribution, this approach incorporates
all observed information on the repeated measures of the outcome to produce estimates that are valid under a
MAR assumption. No explicit imputation is involved. For outcomes collected at a limited number of fixed time
points following randomization, a LMM would typically include fixed effects for time (categorical), randomized
group and the interaction between randomized group and time. Within-subject dependence due to repeated
measurements is accounted for through specification of a covariance structure. Several authors have
recommended the unstructured covariance matrix since it is easily pre-specified, entails minimal power loss
compared with more parsimonious choices9,42,43 and ensures that estimates are approximately equivalent to
and slightly more efficient than those obtained from a comparable MI procedure.9,14 With a single intermediate
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In applying MI, the repeated measurements of the outcome are usually treated as distinct variables in the
imputation model. Where interest lies in the treatment effect at the final time point, the analysis model need not
include the intermediate outcome measures; following imputation a comparison of final time point results is
sufficient.44 In this case, the intermediate measures operate as auxiliary variables, assisting with the prediction
Figure 3. Mean average treatment effect estimates for 50% missing data in a binary outcome under the MAR X mechanism (odds of
Y missing 1.5 (weak MAR) or 2.5 (strong MAR) times higher per standard deviation increase in X), incorrectly specified analysis model.
Horizontal reference lines illustrate the least false average treatment effect in the absence of missing data. Error bars correspond to
empirical standard errors (1 standard error) across 2000 simulated datasets.
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of missing values at the final time point and making the MAR assumption more plausible. Other auxiliary
variables, for instance measures of compliance or related outcomes, can also be added to the imputation model
as required. If data are collected but more likely to be missing following treatment discontinuation, an indicator
variable for discontinuation may also be valuable as an auxiliary variable. The ability to incorporate auxiliary
variables, both for univariate and multivariate outcomes, is considered one of the key strengths of MI.45 Less well
known is that LMMs can also benefit from auxiliary variables through joint modelling with the outcome.9,46 Using
model (2) for illustration, Z could be an auxiliary variable rather than an intermediate outcome measure. By
assuming an unstructured covariance matrix, multiple auxiliary variables are easily handled within a LMM.9
For the simulation study, intermediate (Z) and final ðYÞ values of a continuous outcome were simulated from




Y ¼ 1. To evaluate whether the correlation between Z and
Y impacted on model performance, we considered ZY ¼ 0:30 or 0:70. We also examined both weak (0.30) and
strong (0.70) correlations between X and the outcome measures. Following generation of complete datasets, values
in Y were set to missing such that the odds of missingness were l times higher per SD increase in Z (with l¼ 1.5 or
2.5 and for 20% or 50% missing data). In addition to CCA and MI, data were analysed using a LMM with an
unstructured covariance matrix. Treatment effect estimates for LMMs in this article were obtained using restricted
maximum likelihood estimation with degrees of freedom calculated according to the Kenward–Roger method.47
MI overall, MI by group and the LMM produced unbiased treatment effect estimates across the 16 simulation
scenarios (4 missing data scenarios 4 correlations), with coverage 0.94 throughout. Compared to the LMM,
empirical SEs were on average 0.5% and 3.2% higher with MI overall and MI by group, respectively. The lost
efficiency with MI by group was most noticeable in scenarios with 50% missing data and a strong MAR
mechanism. Power was on average 0.3% lower for MI overall and 2.2% lower for MI by group compared to
the LMM. By ignoring the intermediate measure of the outcome, CCA was, as expected, the least efficient
approach. Although minimal in most settings, some bias was also evident with CCA. Figure 4 illustrates
performance in scenarios with 50% missing data, a strong MAR mechanism and where corrðX,YjTÞ ¼ 0:30.
As seen in the figure, the relative performance of CCA was poor for ZY ¼ 0:70 (bias¼ 0.03, empirical SE
10.7% larger than the LMM). While outperforming CCA, MI offered no advantages over the LMM.
Figure 4. Mean treatment effect estimates for 50% missing data in a continuous multivariate outcome, corr(X,YjT)¼ 0.30, strong
missing at random (MAR) mechanism. Error bars correspond to empirical standard errors (1 standard error) across 2000 simulated
datasets.
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Similar results were obtained from a simulation study allowing missing data to occur in the intermediate as well
as the final measure of the outcome, although the shortcomings of CCA were less pronounced in this setting (see
online Appendix B). We did not consider a simulation study for binary multivariate outcome data due to
complexities in defining the estimand (see Discussion).
6 Missing data in a baseline covariate
Although missing baseline data can be avoided by requiring complete data collection before randomization, this
may not always be feasible (e.g. if a lengthy baseline interview is required). Unless baseline data are missing by
design, it is implausible that missingness depends on randomized group given that baseline variables are measured
before randomization.9,48 In this context, group comparisons based on complete cases should be unbiased, even if
baseline data are MNAR. One potential limitation of the standard implementation of MI for imputing missing
baseline data is that it ignores the independence of X and T. Chance imbalances in X in the observed data are
incorrectly extrapolated to the missing data, which may result in a loss of efficiency.48 In this section, we evaluate
the efficiency of MI using simulation, both for continuous and binary variables, and compare performance with
alternative approaches.
6.1 Continuous baseline covariate and outcome
The binary indicatorMXi for missing data in the baseline covariate X was first simulated with a probability of 0.20.
Unlike other scenarios, we did not consider 50% missing data, since this degree of missingness seems unlikely for a
baseline covariate pre-specified for adjustment. Next, baseline and outcome data were simulated from the models
Xi ¼ XMXi þ e1i and Yi ¼ 0:30Ti þ 2Xi þ YMXi þ e2i, with e1 and e2  Nð0, 1Þ. The parameters X and Y in
these models allow X and Y, respectively, to be associated with MXi. Both MCAR (X ¼ Y ¼ 0) and MNAR
(X ¼ Y ¼ 0:30) mechanisms were considered in separate simulation scenarios. In choosing values for 2, we
allowed corr X,YjT,MX ¼ 0ð Þ to range between 0.10 and 0.90 in increments of 0.20.
In addition to MI and CCA, we evaluated the performance of mean imputation, the missing indicator method
and a LMM with baseline as an outcome. In mean imputation, missing baseline values are replaced with the mean
of the observed values across both groups (i.e. Xi ¼
Xobs if MXi ¼ 1). Although mean imputation for addressing
missing outcome data has been widely criticized for failing to incorporate missing data uncertainty,2,8 overstated
precision is not a concern in this setting given the independence of X and T and interest only in the effect of
treatment (and not the effect of the covariate).48 The missing indicator method involves mean imputation and the
addition of a dummy variable indicating missing data to the analysis model (i.e. adding MXi). Despite being
inappropriate for general use,49,50 the missing indicator method has been validated for addressing missing
covariate data in RCTs, where X and T are independent and missingness in X is conditionally independent of
Y.48,51 For strong correlations between X and Y, White and Thompson48 found that mean imputation and the
missing indicator method became more efficient when participants with missing data were given a weight of
1 corr X,YjT,MX ¼ 0ð Þ
2 in the analysis (with observed cases retaining a weight of 1). We investigated both
unweighted and weighted approaches. For the LMM, we considered a joint model for X and Y, where X was














Under both MCAR and MNAR mechanisms, all methods produced unbiased treatment effect estimates with
nominal coverage throughout (range 0.94, 0.96). Despite this, noticeable differences in efficiency were apparent
across the different approaches to handling missing data. Figure 5 summarizes performance under the MCAR
mechanism for corr X,YjT,MX ¼ 0ð Þ ¼ 0.10, 0.50 and 0.90. As seen in the figure, CCA was close to optimal for a
strong correlation between X and Y but inefficient for weak to moderate correlations. Both mean imputation and
the missing indicator method performed well, with weighting becoming important for strong correlations. MI was
marginally less efficient than the weighted approaches and the LMM (empirical SEs on average 0.3% larger), with
little difference seen between MI overall and MI by group. Lastly unadjusted CCA was highly inefficient for
moderate to strong correlations between X and Y. Efficiency results under the MNAR mechanism closely mirrored
those of the MCAR mechanism, with MI performing similarly to weighted mean imputation and the LMM across
all values for corr X,YjT,MX ¼ 0ð Þ (empirical SEs on average 0.3% larger with MI overall and MI by group than
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mean imputation and the LMM). Interestingly, the missing indicator method incorporating weights held a slight
advantage over MI under the MNAR mechanism (empirical SEs on average 1.1% smaller than with MI), which
can be attributed to inclusion of the prognostic variable MX in the analysis model. A graphical summary of
performance under the MNAR mechanism is shown in online Appendix C; we do not present results here given
their similarity to the MCAR setting. Given the simplicity of alternative approaches to handling missing data in
baseline covariates, there appears to be little reason to adopt MI in this setting.
6.2 Binary baseline covariate and outcome
Following simulation of MXi with probability 0.20, baseline and outcome data were generated from the models
logit PðXi ¼ 1Þ ¼ XMXi and logit PðYi ¼ 1Þ ¼ 0 þ 0:69Ti þ 2Xi þ YMXi. The coefficient 2 was varied, so that
ORðY,XjT,MX ¼ 0Þ ¼2.0, 4.0 or 8.0, while 0 was chosen to give P Y ¼ 1jT ¼ 0,MX ¼ 0ð Þ ¼ 0:20. Both MCAR
(X ¼ Y ¼ 0) and MNAR (X ¼ Y ¼ 0:69) mechanisms were considered. We did not consider weighted methods
or a LMM as in the continuous case, since these approaches are not applicable for binary outcomes.
Mean treatment effect estimates and empirical SEs for the MCAR mechanism are displayed in Figure 6.
The clear outlier on these performance measures was unadjusted CCA. Since adjustment in logistic regression
has the effect of increasing SEs and producing odds ratios that are further from the null,52 this finding is not
surprising. Both MI overall and MI by group produced unbiased treatment effect estimates (absolute bias 0.004)
with nominal coverage (range 0.95, 0.96) throughout, with little difference in empirical SEs between approaches.
CCA produced treatment effect estimates with minimal bias, however empirical SEs were on average 10% larger
than those of MI. For mean imputation and the missing indicator method, we observed a trade-off between
efficiency and bias. For ORðY,XjT,MX ¼ 0Þ ¼ 8.0, both approaches exhibited modest efficiency advantages
over MI (empirical SEs 4% smaller) at the expense of a small bias (0.02) towards the null. In terms of
average power, there were minimal differences between mean imputation (93.0%), the missing indicator method
(93.0%) and the MI approaches (92.9%). The small bias of mean imputation and the missing indicator arises
because the methods estimate a treatment effect that lies between the marginal (unadjusted) and conditional
(adjusted) estimands. As the proportion of missing data in X is increased, the methods shift from estimating
the conditional estimand with no missing data to estimating the marginal estimand with no observed data
Figure 5. Mean treatment effect estimates for 20% missing data in a continuous baseline covariate, MCAR mechanism. Error bars
correspond to empirical standard errors (1 standard error) across 2000 simulated datasets.
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(results not shown). Since for logistic regression the marginal estimand is always closer to the null, mean
imputation and the missing indicator method produce estimates of the conditional treatment effect that are
biased towards the null.
Although for Y 6¼ 0 the omission ofMX from analysis models changes the treatment effect estimated by logistic
regression, the observed changes were minimal across the MNAR scenarios considered. Based on complete data,
the ‘least false’ treatment effect from a misspecified model omitting MX was approximately 0.68 for all values of
ORðY,XjT,MX ¼ 0Þ. That distinction aside, results from the MNAR setting closely followed those of the MCAR
setting (see Figure 7). In comparing MI with mean imputation, we once again observed a trade-off between
efficiency and bias. For OR Y,XjT,MX ¼ 0ð Þ ¼ 8:0, the empirical SE of mean imputation was 4.7% smaller
than MI; however, the bias was slightly more pronounced (0.05 vs. 0.02). The missing indicator method
performed similarly to mean imputation in terms of efficiency, however biases were smaller in magnitude with
the missing indicator method due to correct specification of the analysis model. Excluding unadjusted CCA, all
methods produced treatment effect estimates with correct coverage (range 0.94, 0.95).
7 Case study
The Docosahexaenoic Acid for the Improvement of Neurodevelopmental Outcome in Preterm Infants (DINO)
trial was a blinded RCT conducted in five Australian hospitals between 2001 and 2007 (Australian New Zealand
Clinical Trials Registry: ACTRN12606000327583). Preterm infants born <33 weeks gestation (n¼ 657) were
randomized to receive a high docosahexaenoic acid (DHA) or a standard DHA diet from within 5 days of
commencing enteral feeds through to term. Randomization was stratified by hospital, sex and birth weight
(<1250 g, 1250 g), with infants from a multiple birth randomized according to the sex and birth weight of
the first born infant. Results for primary and key secondary outcomes have been published previously.53–55
In the primary trial publication,53 outcomes were re-analyzed using MI following feedback from reviewers that
all randomized infants had to be included in ITT analyses and that MI would be an appropriate approach to
achieve this. To simplify the dataset for illustration purposes, second and subsequent born infants from a multiple
birth and infants that died before term were ignored, resulting in an example dataset with 262 and 260 infants in
the high and standard DHA groups, respectively.
Figure 6. Mean treatment effect estimates for 20% missing data in a binary baseline covariate, MCAR mechanism. OR (odds ratio)
refers to OR(X,YjT). Error bars correspond to empirical standard errors (1 standard error) across 2000 simulated datasets.
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To illustrate approaches for handling missing outcome data, we consider comparisons of fat free mass (FFM)
at 7 years corrected age. Excluding two children that died after term, FFM was missing for 65/262 (24.8%) and
46/258 (17.8%) children in the high and standard DHA groups, respectively. Logistic regression analysis
revealed differences between the five study centres in the odds of missing outcome data (global p-value¼ 0.03).
No other predictors of missing data were identified. For predictors of the outcome, linear regression analysis
revealed associations between FFM and centre, sex and weight, height and systolic blood pressure at 7 years
corrected age. Since centre and sex were baseline measures, for illustration purposes we imagine these variables
were pre-specified as covariates for adjustment. Weight, height and systolic blood pressure at 7 years corrected age
were treated as auxiliary variables.
We estimated the effect of treatment using CCA, MI overall, MI by group and a LMM. An unadjusted CCA
was also conducted for comparison. Since the auxiliary variables contained missing data (approximately 10% for
each variable), values were imputed using a Markov chain Monte Carlo algorithm assuming multivariate
normality.14 Following a burn-in of 5000 iterations, m¼ 50 completed datasets were created. For the LMM,
the three auxiliary variables and FFM were jointly modelled assuming an unstructured covariance matrix, with
adjustment for centre and sex.
Treatment effect estimates are presented in Table 1. Although there was little evidence for an effect of treatment
on FFM, subtle differences between the approaches are apparent. As expected, adjustment for prognostic baseline
covariates in a CCA reduced the SE of the treatment effect estimate compared with the unadjusted analysis. By
incorporating information from auxiliary variables, additional efficiency gains were evident for MI and the LMM,
with similar estimates from the two approaches (as expected). However gains were small, perhaps because 48% of
the children with a missing FFM value also had missing data on the three auxiliary variables. Even when fully
observed, auxiliary variables may only have a meaningful impact on estimation when strongly correlated with the
outcome.45,56,57
For missing data in a baseline covariate, we consider group comparisons of head circumference (HC) at term
adjusted for birth HC. To focus on the problem of missing baseline data, 20 infants with missing outcome data
were excluded from the analysis. Seven of these infants were missing birth HC and hence contained no information
for estimating treatment effects, while the remaining 13 were assumed to be MAR and hence could be validly
excluded (as demonstrated in Section 4). Of the remaining infants, birth HC was missing for 39/251 (15.5%) and
Figure 7. Mean treatment effect estimates for 20% missing data in a binary baseline covariate, MNAR mechanism. OR (odds ratio)
refers to OR(X,YjT). Error bars correspond to empirical standard errors (1 standard error) across 2000 simulated datasets.
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42/251 (16.7%) in the high and standard DHA groups, respectively. Treatment effects were estimated using
the same methods as in Section 6.1, with 50 imputations used for MI. In relation to the calculation of weights
for mean imputation and the missing indicator method, in complete cases, the correlation between birth HC and
HC at term was 0.43.
As illustrated in Table 2, estimates were similar across the nine statistical approaches. In line with simulation
results for a moderate correlation between the baseline and outcome measure, CCA and unadjusted CCA
produced the largest SEs for the effect of treatment. While outperforming CCA, MI did not offer any efficiency
improvements over the remaining approaches.
Since the probability of missing baseline data differed across the five study centres, we considered additional
sensitivity analyses where centre was added as a covariate in adjusted models and mean imputation was performed
separately by centre. Although this resulted in small increases in precision compared to models ignoring centre,
again MI did not outperform simpler approaches such as mean imputation and the missing indicator method with
or without weights (SE¼ 0.123 for all approaches).
8 Discussion
In this article, we evaluated the performance of MI in the RCT setting. In line with theoretical results, in its
standard implementation, MI produced unbiased treatment effect estimates when data were MAR and the analysis
model was correctly specified. However, due to Monte Carlo simulation error, MI was often less efficient than
alternative unbiased approaches. For missing outcome data, MI was less efficient than CCA for univariate
outcomes and the LMM for multivariate outcomes. For missing data in a baseline covariate, MI failed
to outperform methods such as mean imputation and the missing indicator method. As well as being less
efficient, MI was generally more difficult to implement and took longer to run compared with alternatives.
Being a stochastic analysis, it also had the disadvantage of not producing a unique treatment effect estimate.
Table 2. Treatment effect estimates for head circumference (cm) at term from the









Unadjusted CCA 0.060 0.136 0.326, 0.206
CCA 0.058 0.134 0.320, 0.204
MI overall m¼ 50 0.023 0.125 0.267, 0.221
MI by group m¼ 50 0.027 0.125 0.273, 0.218
Mean imputation 0.024 0.125 0.269, 0.221
Mean imputation with weights 0.029 0.125 0.274, 0.215
Missing indicator 0.028 0.125 0.272, 0.217
Missing indicator with weights 0.032 0.124 0.276, 0.211
Linear mixed model 0.029 0.125 0.275, 0.217
Table 1. Treatment effect estimates for fat free mass (kg) at 7 years corrected age from the










Unadjusted CCA 0.007 0.259 0.514, 0.500
CCA 0.048 0.238 0.420, 0.515
MI overall m¼ 50 0.104 0.233 0.562, 0.353
MI by group m¼ 50 0.118 0.227 0.563, 0.327
Linear mixed model 0.097 0.231 0.551, 0.356
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Given these limitations, we believe that MI should not be seen as the only acceptable way to address missing
data in RCTs.
Collectively, our results underline the importance of context in choosing an approach for handling missing data.
While MI is an extremely useful general purpose tool, it appears most beneficial in observational settings when
there are missing data in confounding variables.58 In RCTs, some of the value of MI is lost, and other approaches
that are not widely recommended can be employed. For example, our simulation results confirm that mean
imputation and the missing indicator method, whose use is ill-advised in most settings,2,8,49,50 can be validly
applied for addressing missing covariate data in RCTs. Similarly, despite general recommendations against the
use of CCA,2,8 it is optimal when missing data are restricted to a univariate outcome and variables associated with
missingness are included as covariates in the analysis model.34–36 This scenario seems most pertinent to RCTs,
where missing data tend to occur in the outcome. Of course should post-randomization auxiliary variables for a
univariate outcome be available, as is often the case, we then move into the setting of multivariate data and
approaches such as MI or a LMM should be preferred over CCA.
Regarding choice of imputation strategy, we found that MI by group was slightly less efficient than MI overall
for a correctly specified analysis model. However, when the analysis model overlooked an interaction effect
involving randomized group, only MI by group produced unbiased estimates of the ATE. Thus in settings
where MI is adopted, we recommend imputing by randomized group; compared to MI overall, this approach
offers greater robustness at little cost. The approach is also consistent with general recommendations for over-
rather than under-specifying imputation models.14,45 It should be noted that imputing by group only protects
against bias in estimating the ATE if effect modifiers are included in the imputation model. Another possibility is
to include interaction terms in a single imputation model, but this approach is more complex and may not be
obvious when analysis models do not include interaction terms. Although not considered in this article, we agree
with previous recommendations for performing imputation separately by randomized group in settings involving
subgroup analyses.11,20–22
Despite highlighting alternatives to MI in this article, we are not suggesting that it is inappropriate to use MI.
To the contrary, we view MI as an attractive option given its considerable flexibility. It is not uncommon in RCTs
for researchers to collect data on a large number of secondary outcomes. One of the strengths of MI is its ability to
easily incorporate variables of different types (e.g. continuous, binary) in the imputation model, whether for
univariate or multivariate data. An added benefit of including all outcomes in a single imputation model is that
associations between related outcomes can aid imputation. Another appealing feature of MI is its ability to be
implemented under an assumption that data are MNAR. This property makes MI well suited to undertaking
sensitivity analyses around a primary assumption that data are MAR,59 and as a primary method of analysis in
settings where data are believed to be MNAR. One such setting is RCTs where participants cannot followed up
after discontinuing treatment. If all observed data are ‘on-treatment’, a MAR assumption entails estimating the
effect of treatment had all participants remained on their assigned treatment.27 However, for a de facto type
estimand (such as ITT), it may be more appropriate to assume that data are MNAR. In this situation, reference-
based sensitivity analyses have been proposed, which at present require the use of MI.23
A limitation of the current study is that conclusions were based on a restricted set of simulation scenarios.
Although we only considered simple randomization to two groups, we anticipate that findings would extend to
RCTs involving three or more randomized groups, unequal allocation probabilities and randomization using
stratified blocks or minimization. We also expect that our results for normally distributed and binary outcome
variables would apply to most other outcome types. Three exceptions worth noting are time to event outcomes,
where missing outcome data can be addressed via censoring, composite (scale) outcomes derived from multiple
items and binary multivariate outcomes. For missing data in a composite outcome, MI at the item level is a
particularly convenient approach when the individual items are partially observed. Although likelihood-based
alternatives for composite outcomes are also available,60 they are more difficult to implement. For binary
multivariate outcomes, complexities arise due to differences between population-averaged and subject-specific
estimands.61 Generalized mixed models can be implemented in a similar manner to LMMs for continuous data
if subject-specific estimates are of interest9; however, these models can be challenging to fit given the variety of
estimation procedures available and the computational difficulties that can arise with large numbers of repeated
measurements.62 MI is more appealing for producing population-averaged estimates.9
A further limitation is that we did not consider the performance of inverse probability weighting (IPW).
This approach, which involves weighting complete cases by the inverse of the probability of being a complete
case, requires only a correctly specified model for the probability of missing data to produce valid estimates under
a MAR assumption. However, IPW tends to be less efficient than MI and can be difficult to implement for
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non-monotone missing data patterns.63 Of relevance to the settings considered in this article, IPW is capable of
producing population-averaged estimates for multivariate binary outcome data and unbiased estimates of an ATE
from a misspecified analysis model.63 IPW can also be appropriate in settings where data are missing by design and
hence where the probability of being a complete case is known. We also did not evaluate multiple imputation then
deletion, which is a modification to standard MI where participants with imputed outcomes (but not imputed
covariate values) are deleted from analysis datasets.64 The rationale behind this approach is that following
imputation, participants with missing outcomes only contribute noise to the estimation procedure.64 Whether
MID is useful in the RCT setting is debatable however, since it is only applicable in settings where both covariate
and outcome data are missing. Further, the approach should be avoided when auxiliary variables for the outcome
are included in the imputation model,65 as is often the case.
In summary, MI is not the only option for handling missing data in RCTs. Although MI is appropriate in all
contexts, simpler alternatives are often slightly superior. For missing outcome data, MI can be inferior to CCA
and likelihood-based approaches, adding in unnecessary simulation error. For missing data in a baseline covariate,
simpler approaches such as mean imputation and the missing indicator method can outperform MI. Should MI be
adopted, we recommend imputing separately by randomized group.
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